Evaluating the Safety and Efficacy of Rupatadine in the Treatment of Nonalcoholic Fatty Liver Disease Patients.

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
NAFLD is characterized by excessive hepatic fat accumulation without other recognized causes of increased fat content (e.g., alcohol, virus, drugs, and autoimmunity). According to the Clinical Practice Guidelines of the European Association for the Study of the Liver, the diagnosis of NAFLD requires the exclusion of daily alcohol consumption \>30 g for men and \>20 g for women
Epistemonikos ID: c0aee84b1813b16a17af815526988773903ca6da
First added on: Oct 29, 2026